|
KMID : 0942820080070010044
|
|
Journal of Korean Brain Tumor Society
2008 Volume.7 No. 1 p.44 ~ p.49
|
|
|
Cytotoxicity of Temozolomide and Cetuximab for the Epidermal Growth Factor Receptor-positive GL26 Murine Glioma Cells
|
|
Jeong Dong-Sup
Kim Eun-Kyoung
Hong Yong-Kil
|
|
|
Abstract
|
|
|
Objective: The monoclonal antibody of epidermal growth factor receptor(EGFR) cetuximab was effective against EGFRamplified glioblastoma cells. Moreover, recent clinical trials showed that targeted therapies such as cetuximab are more effective in the malignant tumors when given with other chemotherapeutic agents. The purpose of the present study was to evaluate the in vitro responsiveness of combined temozolomide(TMZ) and cetuximab treatment as well as TMZ or cetuximab monotherapy against EGFR-positive GL26 murine glioma cells.
Methods: The expression of EGFR was evaluated in GL26 cells using immunocytochemistry for the EGFR antibody. Murine GL26 glioma cells were treated with various concentrations of combined TMZ and cetuximab, TMZ or cetuximab. The responses to the treatments were evaluated for 5 days using cytotoxicity assay.
Results: EGFR was expressed in GL26 glioma cells, but cetuximab did not show a significant cytotoxic effect against these EGFR-positive glioma cells. Although TMZ monotherapy showed cytotoxicity against GL26 cells, combination of TMZ and cetuximab did not lead to additive cytotoxic effect.
Conclusion: EGFR-positive GL26 murine glioma cells may not respond to the cetuximab and have no additive response to combined TMZ and cetuximab. Further investigations on cellular mechanisms and cytotoxic pathways triggered by the reaction of glioma cells to cetuximab are needed.
|
|
|
KEYWORD
|
|
|
Epidermal growth factor receptor, Cetuximab, Temozolomide, GL26 murine glioma cells
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|